Federal Register / Vol. 79, No. 199 / Wednesday, October 15, 2014 / Notices 61879 

treatment of various human cancers 

expressing 5T4. 

Competitive Advantages: 

• The fully human antibodies may 

have better drugability, especially less 

immunogenicity and better safety. 

• This antibodies could be used as 

naked mAbs, CARs and/or as ADCs. 

• The confined expression of 5T4 

makes it an attractive target for cancer 

immunotherapy. 

• 5T4 mAbs could be used to treat 

several solid tumor cancers. 

Development Stage: In vitro data 

available 

Inventors: Dimiter Dimitrov, Tianlei 

Ying, Yang Feng (all of NCI) 

Intellectual Property: HHS Reference 

No. E–158–2014/0—U.S. Provisional 

Application No. 62/034,995 filed 08 

August 2014 

Licensing Contact: Whitney Hastings; 

301–451–7337; hastingw@mail.nih.gov 

Quantitative Multiplex Methods for 

Rapid Detection and Identification of 

Viral Nucleic Acids 

Description of Technology: The 

subject technologies are quantitative 

multiplex loop mediated isothermal 

amplification assays that can detect and 

distinguish different viral pathogens, 

including HIV, Hepatitis B Virus (HBV), 

Hepatitis C Virus (HCV), Hepatitis E 

Virus (HEV), Dengue Virus (DENV), 

Chikungunya virus (CHIKV) and West 

Nile Virus (WNV). The assay has the 

advantage of distinguishing between 

different genotypes of HCV. It has the 

potential to detect other pathogens. A 

quantitative multiplex variation of the 

assay can detect and identify all seven 

viruses using one reaction mixture. The 

detection-reaction is performed on a 

simple heat-source and viral 

quantitation can be measured using a 

simple fluorospectrophotometer. The 

entire detection process using these 

assays can be accomplished within 30 to 

60 minutes in a doctor’s office, 

laboratory setting, or in the field. 

Detection limits of as little as 1–10 

International Units (viral copies) are 

possible with the use of fluorogenic 

oligonucleotides. The assays 

demonstrate very high specificity when 

tested with human clinical samples. 

Potential Commercial Applications: 

Detection assays for viral pathogens 

such as HIV, HBV, HCV, HEV, Dengue 

Virus, Chikungunya, and West Nile 

Virus. 

Competitive Advantages: 

• Assays can be completed within 30 

to 60 minutes and in a doctor’s office, 

laboratory setting, or in the field. 

• Assays can be performed without 

expensive instrumentation or 

specialized technical operators. 

• Assays are highly specific and can 

distinguish between different viruses 

and between different genotypes of 

viruses. 

Development Stage: 

• Early-stage 

• In vitro data available 

• In vivo data available (human) 

Inventors: Dougbeh-Chris Nyan 

(FDA), Deborah R. Taylor (FDA), Maria 

Rios (FDA), Kevin L. Swinson (Morgan 

State University), Laura E. Ulitzky 

(FDA) 

Publication: Nyan DC, et al. Rapid 

Detection of Hepatitis B Virus in Blood 

Plasma by a Specific and Sensitive 

Loop-Mediated Isothermal 

Amplification Assay. Clin Infect Dis. 

2014 July 1;59(1):16–23. [PMID 

24704724] 

Intellectual Property: HHS Reference 

No. E–135–2014/0—US Provisional 

Patent Application No. 61/979,446 filed 

14 April 2014 

Licensing Contact: Kevin W. Chang, 

Ph.D.; 301–435–5018; changke@

mail.nih.gov 

Collaborative Research Opportunity: 

The Food and Drug Administration, 

Center for Biologics Evaluation and 

Research, is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate or 

commercialize blood screening test and/ 

or diagnostic test for infectious diseases. 

For collaboration opportunities, please 

contact Nisha Narayan at 

Nisha.Narayan@fda.hhs.gov or 240– 

402–9770. 

Dated: October 8, 2014. 

Richard U. Rodriguez, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. 2014–24403 Filed 10–14–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Center for Scientific Review; Amended 

Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Center for Scientific 

Review Special Emphasis Panel, 

October 27, 2014, 07:30 a.m. to October 

28, 2014, 06:00 p.m., Doubletree Guest 

Suites Santa Monica, 1707 Fourth 

Street, Santa Monica, CA, 90401 which 

was published in the Federal Register 

on October 06, 2014, 79 FR 60175. 

The meeting will start on October 27, 

2014. The meeting time and location 

remains the same. 

The meeting is closed to the public. 

Dated: October 7, 2014. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2014–24380 Filed 10–14–14; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Library of Medicine; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App), notice is 

hereby given of meetings of the Board of 

Regents of the National Library of 

Medicine. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable materials, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Board of Regents of 

the National Library of Medicine; Extramural 

Programs Subcommittee. 

Date: February 10, 2015. 

Closed: 7:45 a.m. to 8:45 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Library of Medicine, 

Building 38, Billings Conference Room, 8600 

Rockville Pike, Bethesda, MD 20892. 

Contact Person: Donald A.B. Lindberg, MD, 

Director, National Library of Medicine, 8600 

Rockville Pike, Bethesda, MD 20892, 301– 

496–6221, lindberg@mail.nih.gov. 

Name of Committee: Board of Regents of 

the National Library of Medicine; 

Subcommittee on Outreach and Public 

Information. 

Date: February 10, 2015. 

Open: 7:45 a.m. to 8:45 a.m. 

Agenda: To review and discuss outreach 

activities. 

Place: National Library of Medicine, 

Building 38, 2nd Floor, Conference Room B, 

8600 Rockville Pike, Bethesda, MD 20892. 


tkelley on DSK3SPTVN1PROD with NOTICES